Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $20.96, for a total value of $314,400.00. Following the completion of the sale, the insider owned 334,786 shares of the company’s stock, valued at $7,017,114.56. This represents a 4.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.04, for a total value of $300,600.00.
• On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.27, for a total value of $304,050.00.
• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.60, for a total value of $384,000.00.

Kestra Medical Technologies Trading Up 1.1%

NASDAQ KMTS opened at $19.80 on Wednesday. The stock has a 50-day simple moving average of $20.59 and a 200 day simple moving average of $23.81. The company has a market capitalization of $1.16 billion, a PE ratio of -5.00 and a beta of 0.82. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm’s quarterly revenue was up 62.7% on a year-over-year basis. Research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

Wall Street Analyst Weigh In

KMTS has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, The Goldman Sachs Group reduced their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $27.40.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of hedge funds have recently added to or reduced their stakes in KMTS. Price T Rowe Associates Inc. MD increased its stake in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after acquiring an additional 2,529,851 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter valued at $11,036,000. Brown Advisory Inc. lifted its holdings in Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after buying an additional 428,996 shares during the period. Finally, Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies during the 4th quarter worth about $9,282,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.